Biomarkers to Guide Immunotherapy Treatment of Solid Tumors: Strategies to Promote Best Practices for Quality Care Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, November 15, 2015

Biomarkers to Guide Immunotherapy Treatment of Solid Tumors: Strategies to Promote Best Practices for Quality Care



CCO

Source: Biomarkers to Guide Immunotherapy Treatment of Solid Tumors: Strategies to Promote Best Practices for Quality Care

Module

Robert A. Anders, MD, PhD; Michael B. Atkins, MD; Naiyer Rizvi, MD; and Janis M. Taube, MD, MSc, discuss the evolving role of biomarkers to identify patients with cancer most likely to benefit from immune checkpoint inhibitors.

 Learning Objectives
Upon completion of this activity, participants should be able to:
  • Describe the role of the immune system in pathogenesis and cancer
  • Explain the mechanism of action and targeted pathways of various classes of immunotherapies
  • Describe the status of emerging biomarkers being evaluated in clinical trials that may affect immunotherapy treatment decisions in the near future
  • Identify patients with cancer who are likely to benefit from treatment with immunotherapy

Topics covered include:

  • The Immune System in Cancer
  • The Immune Response to Cancer and Opportunities for Active Immunotherapy
  • Immune Checkpoint Blockade
  • PD-L1 as a Potential Biomarker for Immune Checkpoint Inhibitors
  • The Status of PD-L1 Biomarker Testing in the Clinic
  • Other Investigational Biomarkers for Immune Checkpoint Inhibitors

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.